Benzinga | Apr 7, 2021 07:55AM EDT

AIM ImmunoTech On Apr. 5 Approved Proposal From Polysciences For Manufacture Of AIM's Poly I And Poly C12U polynucleotides; Seperately Entered MArerial Transfer And Research Agreement With University of Cagliari Dipartimento di Scienze della Vita e dell'A

AIM ImmunoTech Inc. ("AIM" or "Company") has recently entered into two agreements.



On April 5, 2021, the Company approved a proposal from Polysciences Inc. ("Polysciences") for the manufacture of AIM's Poly I and Poly C12U polynucleotides and associated test methods at Polysciences' Warrington, Penn. location to enhance the Company's capacity to produce the polymer precursors to the drug Ampligen. The Company is working with Polysciences to finalize a Service Agreement and a Quality Agreement.



On April 5, 2021, the Company entered into a Material Transfer and Research Agreement (MTA) with the University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente (UNICA), an educational institution under the laws of Italy, located in Monserrato (Cagliari), Italy. The MTA relates to the research and development of the effects of AIM's drug Ampligen and its ability to induce interferon production in several cell lines and also on the ability of the Ebola virus protein VP35 to bind to viral dsRNA and impede interferon's upregulation and activity, and on Ampligen's ability to reverse VP35 inhibition of interferon production in biological systems.